For patients with mitral valve prolapse (MVP) and mitral regurgitation (MR), mitral annular disjunction (MAD) is associated ...

New data from a large, international registry showed balloon-assisted anterior mitral leaflet modification (BATMAN) was safe, ...

This is according to a new study, "Mitral annular disjunction and mitral valve prolapse: long-term risk of ventricular arrhythmias after surgery" from Karolinska Institutet and Karolinska ...

By group, procedural success and freedom from LVOT obstruction (LVOT mean gradient > 50 mm Hg), the primary efficacy endpoint ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as the world’s first transfemoral transcatheter mitral valve replacement ...

Mitral annular disjunction and mitral valve prolapse: long-term risk of ventricular arrhythmias after surgery. European Heart Journal , 2025; DOI: 10.1093/eurheartj/ehaf195 Cite This Page : ...

Mitral annular disjunction, MAD, is a heart abnormality in which the mitral valve attachment 'slides'. In recent years, the condition has been linked to an increased risk of severe cardiac ...

Mitral annular disjunction, MAD, is a heart abnormality in which the mitral valve attachment ‘slides’. In recent years, the condition has been linked to an increased risk of severe cardiac arrhythmias ...

as well as reduced early diastolic mitral annular velocity using tissue Doppler imaging. In late stages with LV failure associated with elevations in left atrial pressure, a so-called restrictive ...

Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery ...

Edwards Lifesciences Corporation, leading global structural heart innovation company, announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment ...